Jazz Pharmaceuticals, Inc. Share Price Nasdaq
Equities
US4721471070
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
|
07-10 | Jazz Pharmaceuticals plc Promotes Samantha Pearce to Chief Commercial Officer | CI |
07-09 | RBC Trims Price Target on Jazz Pharmaceuticals to $175 From $176, Keeps Outperform Rating | MT |
Sales 2024 * | 4.05B 312B | Sales 2025 * | 4.36B 336B | Capitalization | 6.69B 516B |
---|---|---|---|---|---|
Net income 2024 * | 425M 32.77B | Net income 2025 * | 593M 45.72B | EV / Sales 2024 * | 2.44 x |
Net Debt 2024 * | 3.18B 245B | Net Debt 2025 * | 1.84B 142B | EV / Sales 2025 * | 1.96 x |
P/E ratio 2024 * |
18
x | P/E ratio 2025 * |
12.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.22% |
Latest transcript on Jazz Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 28/02/03 |
Renée Galá
PSD | President | 52 | 15/03/20 |
Robert Iannone
CTO | Chief Tech/Sci/R&D Officer | 57 | 28/05/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 28/02/03 |
Norbert Riedel
BRD | Director/Board Member | 66 | 12/05/13 |
Patrick Enright
BRD | Director/Board Member | 62 | 31/12/08 |
1st Jan change | Capi. | |
---|---|---|
+61.53% | 856B | |
+38.95% | 631B | |
-3.66% | 359B | |
+15.06% | 325B | |
+9.18% | 297B | |
+5.89% | 234B | |
+16.53% | 226B | |
+15.67% | 177B | |
+2.47% | 165B |